company background image
JNJ logo

Johnson & Johnson NYSE:JNJ Stock Report

Last Price

US$156.76

Market Cap

US$377.8b

7D

-2.8%

1Y

1.9%

Updated

18 Mar, 2024

Data

Company Financials +

JNJ Stock Overview

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.

JNJ fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends5/6

Narratives

Beta

Narratives bring a range of perspectives from our community.

Johnson & Johnson Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Johnson & Johnson
Historical stock prices
Current Share PriceUS$156.76
52 Week HighUS$175.97
52 Week LowUS$144.95
Beta0.53
1 Month Change0.13%
3 Month Change0.19%
1 Year Change1.87%
3 Year Change-2.33%
5 Year Change14.75%
Change since IPO24,981.64%

Recent News & Updates

Recent updates

Johnson & Johnson: A Clean Bill Of Health

Feb 28

Is There An Opportunity With Johnson & Johnson's (NYSE:JNJ) 43% Undervaluation?

Feb 12
Is There An Opportunity With Johnson & Johnson's (NYSE:JNJ) 43% Undervaluation?

Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds

Feb 10

Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'

Jan 25

Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition

Jan 15

Johnson & Johnson: Rock Solid 3% Yield With Over 10% Return Potential (Rating Upgrade)

Jan 04

We Think Johnson & Johnson (NYSE:JNJ) Can Manage Its Debt With Ease

Dec 26
We Think Johnson & Johnson (NYSE:JNJ) Can Manage Its Debt With Ease

Johnson & Johnson: Ottava Surgical Robot Is A Growth Tailwind

Dec 23

Shareholder Returns

JNJUS PharmaceuticalsUS Market
7D-2.8%-0.3%0.5%
1Y1.9%22.4%29.0%

Return vs Industry: JNJ underperformed the US Pharmaceuticals industry which returned 22.4% over the past year.

Return vs Market: JNJ underperformed the US Market which returned 29% over the past year.

Price Volatility

Is JNJ's price volatile compared to industry and market?
JNJ volatility
JNJ Average Weekly Movement1.8%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: JNJ has not had significant price volatility in the past 3 months.

Volatility Over Time: JNJ's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1886131,900Joaquin Duatohttps://www.jnj.com

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.

Johnson & Johnson Fundamentals Summary

How do Johnson & Johnson's earnings and revenue compare to its market cap?
JNJ fundamental statistics
Market capUS$377.76b
Earnings (TTM)US$13.33b
Revenue (TTM)US$85.16b

28.3x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JNJ income statement (TTM)
RevenueUS$85.16b
Cost of RevenueUS$26.24b
Gross ProfitUS$58.92b
Other ExpensesUS$45.59b
EarningsUS$13.33b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 16, 2024

Earnings per share (EPS)5.53
Gross Margin69.18%
Net Profit Margin15.65%
Debt/Equity Ratio42.6%

How did JNJ perform over the long term?

See historical performance and comparison

Dividends

3.0%

Current Dividend Yield

89%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.